TY - JOUR AB - The present study assessed the safety of outpatient oral anticancer chemotherapeutic drugs by investigating the type and frequency of serious adverse effects (SAEs). Emergency hospitalization, unplanned consultations and telephone calls were investigated in 1,832 patients who received oral anticancer drug treatment at the National Cancer Center Hospital East between December 1, 2014 and November 30, 2015. Oral cytotoxic anticancer and molecular targeted drugs were administrated to 1,140 (62.2%) and 692 (37.8%) patients, respectively. A total of 52 (2.8%) SAEs were reported, with 32 (2.8%) occurring following cytotoxic anticancer drug administration and 20 (2.9%) occurring after molecular targeted drug treatment. The most common SAE was gastrointestinal toxicity. The median time to SAE occurrence was 32 days (range, 5‑1,705 days). The rate of unplanned consultations and telephone calls were 5.5 and 37.9% among all patients, respectively, with skin reactions being the most common reason for unplanned consultations. SAEs often occurred early after treatment initiation. It was concluded that measures against gastrointestinal toxicity are particularly important were administering chemotherapeutic agents. AD - Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Chiba 277‑8577, Japan Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278‑8511, Japan Department of Pharmacy, National Cancer Center Hospital, Tokyo 104‑0045, Japan AU - Kawasumi,Kenji AU - Kujirai,Azusa AU - Matsui,Reiko AU - Kawano,Yohei AU - Yamaguchi,Masakazu AU - Aoyama,Takao DA - 2021/01/01 DO - 10.3892/mco.2020.2174 IS - 1 JO - Mol Clin Oncol KW - oral anticancer drugs serious adverse event emergency hospitalization unplanned consultation telephone calls PY - 2021 SN - 2049-9450 2049-9469 SP - 12 ST - Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study T2 - Molecular and Clinical Oncology TI - Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study UR - https://doi.org/10.3892/mco.2020.2174 VL - 14 ER -